United Therapeutics stock
UTHRNASDAQUnited Therapeutics Corporation, HealthcareISIN US91307C1027
81Score 81 out of 100, Strong
Price and trend
79 / 100
Price history
+29% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 2.5% below its 52-week high. Largest decline in 20 years: 60% (April 2015 to July 2019).
Chart figures for advanced users
- SMA 50$540.58
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$536.84
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$461.54
- The lowest closing price of the last twelve months.
- Resistance$608.49
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- United Therapeutics Corporation belongs to the Biotechnology industry (United States) and, with a market value of $25.27B, is number 15 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.18B (up 10.6% year on year) and earnings of $1.33B (up 11.7%).
- For fiscal 2026, analysts expect on average revenue of $3.23B (up 1.6%) and adjusted earnings per share of $24.93 (down 10.6%).
Show more
- MEQIRI Score 81 out of 100 (Strong): rank 16 of 714 in Healthcare, median 53.
- The P/E is 21.8 (Biotechnology median 21.3, own median of recent years 13.3).
- Our model puts fair value at $835.48, with the price 29% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 38.6% over the last 12 months, Biotechnology median −93.3%.Profitability 93
- More cash than debtCash $2.07B, financial debt $0.Stability 85
- Earnings per share growingUp 20.9% a year since 2020.Growth 76
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are profitability and stability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $642.67 and expensive above $1,193.54 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $1,092.50 (cash-flow model) and $578.45 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $740.27, at 8.2% it would be $974.74.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1.9% on the twelve months before. Revenue has grown strongly since 2006, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating 48%, net 42%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $5.71 (expected $6.01)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 5.4% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $24.93−5.4%
- Revenue
- $3.23B+1.8%
- Earnings per share
- $30.21−0.9%
- Revenue
- $3.64B+2.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −0.6%Results were below expectations; prior 2026 revenue growth expectations are neither reaffirmed nor updated, though the second half is expected to be stronger than the first.
“Based on the trends we're seeing today, we expect the second half of 2026 to be stronger than the first half of 2026, and we remain focused on accelerating revenue growth as we move through the balance of the year. That said, we are not reaffirming or updating any prior revenue growth expectations for 2026 today.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $99.06M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Rothblatt Martine ASale
9 Nov 2026, Chairperson & CEO
- Shares
- 1,614
- Price
- $584.59
- Value
- $943,521
- Rothblatt Martine ASale
9 Nov 2026, Chairperson & CEO
- Shares
- 7,886
- Price
- $572.69
- Value
- $4.52M
- Patusky ChristopherSale
9 Nov 2026, Board
- Shares
- 1,210
- Price
- $580.00
- Value
- $701,800
Show 19 more
- Rothblatt Martine ASale
6 Nov 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $564.51
- Value
- $5.36M
- Rothblatt Martine ASale
5 Nov 2026, Chairperson & CEO
- Shares
- 1,960
- Price
- $597.76
- Value
- $1.17M
- Rothblatt Martine ASale
5 Nov 2026, Chairperson & CEO
- Shares
- 7,540
- Price
- $573.89
- Value
- $4.33M
- Mahon Paul ASale
5 Nov 2026, EVP & GENERAL COUNSEL
- Shares
- 8,300
- Price
- $598.67
- Value
- $4.97M
- Rothblatt Martine ASale
4 Nov 2026, Chairperson & CEO
- Shares
- 1,723
- Price
- $611.06
- Value
- $1.05M
- Rothblatt Martine ASale
4 Nov 2026, Chairperson & CEO
- Shares
- 7,777
- Price
- $599.64
- Value
- $4.66M
- Rothblatt Martine ASale
3 Nov 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $601.92
- Value
- $5.72M
- Rothblatt Martine ASale
2 Nov 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $596.22
- Value
- $5.66M
- Rothblatt Martine ASale
30 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $600.09
- Value
- $5.7M
- Rothblatt Martine ASale
29 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $594.78
- Value
- $5.65M
- Rothblatt Martine ASale
28 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $585.49
- Value
- $5.56M
- Rothblatt Martine ASale
27 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $587.73
- Value
- $5.58M
- Rothblatt Martine ASale
26 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $588.64
- Value
- $5.59M
- Rothblatt Martine ASale
23 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $582.76
- Value
- $5.54M
- Rothblatt Martine ASale
22 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $583.38
- Value
- $5.54M
- Rothblatt Martine ASale
21 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $560.07
- Value
- $5.32M
- Rothblatt Martine ASale
20 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $553.87
- Value
- $5.26M
- Rothblatt Martine ASale
19 Oct 2026, Chairperson & CEO
- Shares
- 9,500
- Price
- $543.32
- Value
- $5.16M
- Rothblatt Martine ASale
16 Oct 2026, Chairperson & CEO
- Shares
- 9,460
- Price
- $534.62
- Value
- $5.06M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at United Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 81
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- GenmabGMAB.CO $32.59B66
- Roivant SciencesROIV $30.32B47
- InsmedINSM $26.49B43
- WuXi Biologics (Cayman)2269.HK $25.42B73
- IncyteINCY $24.92B70
- BioNTechBNTX $21.73B37
- Alnylam PharmaceuticalsALNY $21.41B57
- Innovent Biologics1801.HK $19.29B61
ETFs that hold United Therapeutics
Held by 85 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 3.10% | 0.49% | €26.29M |
| Harbor Health Care UCITS ETF AccW311 | 2.45% | 0.89% | €11.61M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.59% | 0.35% | €1.21B |
Show 5 more
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.59% | 0.49% | €318.39M |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.29% | 0.25% | €44.3M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.72% | 0.30% | €5.27B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.44% | 0.39% | €188.08M |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF USD disUBUS | 0.36% | 0.25% | €127.84M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2022)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.